An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a fragment of a monoclonal antibody directed against MSLN linked to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon intravenous administration of anti-MSLN cFP RO6927005, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization, the toxin moiety is able to kill the MSLN-expressing cancer cells. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
